Abstract
Bispecific antibodies (bsAbs) are a promising novel treatment approach for relapsed/refractory multiple myeloma (MM), but carry the risk of infectious adverse events. An expert infectious disease faculty will co-present this on-demand video with an MM expert to hone skills in identifying risk factors and recognizing the signs and symptoms associated with infectious adverse events of bsAb therapy.
Key Data
-
Publication Date21 August 2024
-
Primary AuthorAjai Chari
-
SourcePRIME Education
-
LanguageEnglish
Click below to visit original source: